Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.
Who will be affected?
Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.
Majithia AR, Erani DM, Kusiak CM, Layne JE, Lee AA, Colangelo FR, Romanelli RJ, Robertson S, Brown SM, Dixon RF, Zisser H
Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study
Medication Optimization Among People With Type 2 Diabetes Participating in a CGM-Driven Virtual Care Program: Prospective Trial
Amit R Majithia;
David M Erani;
Coco M Kusiak;
Jennifer E Layne;
Amy Armento Lee;
Francis R Colangelo;
Robert J Romanelli;
Scott Robertson;
Shayla M Brown;
Ronald F Dixon;
Howard Zisser
ABSTRACT
Background:
The Onduo virtual care program for people with type 2 diabetes (T2D) includes a mobile app, remote lifestyle coaching, connected devices and telemedicine consultations with endocrinologists for medication management and prescription of real-time continuous glucose monitoring (RT-CGM) devices. In a previously described 4-month prospective study of this program, adults with T2D and baseline HbA1c ≥8.0% to ≤12.0% experienced a mean HbA1c decrease of 1.6% with no significant increase in hypoglycemia.
Objective:
The objective of this analysis was to evaluate medication optimization and management in the 4-month prospective T2D study.
Methods:
Study participants received at least 1 telemedicine consultation with an Onduo endocrinologist for diabetes medication management and used RT-CGM intermittently to guide therapy and dosing. Medication changes were analyzed.
Results:
A total of 48 (87%) out of 55 participants had a medication change consisting of a dose change, addition, or discontinuation. Of these, 15 (31%) of participants had a net increase in number of diabetes medications classes from baseline. Mean time to first medication change for these participants was 36 days. The percentage of participants taking a GLP-1 receptor agonist increased from 25% to 56%, while the percentages of participants taking a sulfonylurea or DPP-4 inhibitor decreased from 56% to 33% and 17% to 6%, respectively. Prescriptions of other anti-diabetic medication classes including insulin did not change significantly.
Conclusions:
The Onduo virtual care program can play an important role in providing timely access to guideline-based diabetes management medications and technologies for people with T2D. Clinical Trial: ClinicalTrials.gov NCT0386538
Citation
Please cite as:
Majithia AR, Erani DM, Kusiak CM, Layne JE, Lee AA, Colangelo FR, Romanelli RJ, Robertson S, Brown SM, Dixon RF, Zisser H
Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study